During the 2026 Cyclospora outbreak, persistent watery diarrhea warrants targeted testing, as routine stool studies may miss infection even without international travel.

Daily ensartinib significantly prolonged disease-free survival after chemotherapy and complete resection of ALK-positive NSCLC, supporting biomarker-guided postoperative therapy while long-term survival and safety remain under evaluation.

Fresenius Kabi recalled one morphine injection lot potentially containing hydromorphone, highlighting risks of opioid substitution, barcode failures, respiratory depression, and urgent stock quarantine.

The Second Universal Definition requires compatible symptoms, cardiac abnormalities, and objective evidence supporting heart failure, emphasizing integrated assessment over isolated tests or biomarkers.

FDA expanded teplizumab to ages 8–17 with newly diagnosed stage 3 type 1 diabetes, preserving insulin-producing beta-cell function when treatment begins within six weeks.

Enlicitide is the first oral PCSK9 inhibitor approved for additional LDL-C lowering, offering a convenient option for adults with persistent hypercholesterolemia despite maximally tolerated statins.

Advanced imaging may identify salvageable brain tissue for selected stroke patients receiving IV thrombolysis up to 24 hours after onset, despite increased bleeding risk.

OPTIMA-AF supports stopping P2Y12 therapy after one month in selected AF patients undergoing PCI, reducing clinically important bleeding while maintaining thromboembolic protection.

Tirzepatide significantly reduced obstructive sleep apnea severity and body weight in adults with obesity, supporting FDA-approved treatment alongside lifestyle changes and PAP therapy.

FLOW demonstrated that semaglutide reduced kidney and cardiovascular risks in high-risk adults with type 2 diabetes and albuminuric CKD, supporting broader kidney-protective therapy.